Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author Correction: CDCP1 expression is frequently increased in aggressive urothelial carcinoma and promotes urothelial tumor progression.
Saponaro M, Flottmann S, Eckstein M, Hommerding O, Klümper N, Corvino D, Hosni S, Schmidt A, Mönig N, Schmidt D, Ellinger J, Toma M, Kristiansen G, Bald T, Alimonti A, Ritter M, Hölzel M, Alajati A. Saponaro M, et al. Among authors: bald t. Sci Rep. 2023 Feb 17;13(1):2838. doi: 10.1038/s41598-023-28942-0. Sci Rep. 2023. PMID: 36801926 Free PMC article. No abstract available.
Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Lepletier A, Madore J, O'Donnell JS, Johnston RL, Li XY, McDonald E, Ahern E, Kuchel A, Eastgate M, Pearson SA, Mallardo D, Ascierto PA, Massi D, Merelli B, Mandala M, Wilmott JS, Menzies AM, Leduc C, Stagg J, Routy B, Long GV, Scolyer RA, Bald T, Waddell N, Dougall WC, Teng MWL, Smyth MJ. Lepletier A, et al. Among authors: bald t. Clin Cancer Res. 2020 Jul 15;26(14):3671-3681. doi: 10.1158/1078-0432.CCR-19-3925. Epub 2020 Apr 28. Clin Cancer Res. 2020. PMID: 32345648
CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.
Li XY, Das I, Lepletier A, Addala V, Bald T, Stannard K, Barkauskas D, Liu J, Aguilera AR, Takeda K, Braun M, Nakamura K, Jacquelin S, Lane SW, Teng MW, Dougall WC, Smyth MJ. Li XY, et al. Among authors: bald t. J Clin Invest. 2022 Mar 15;132(6):e159825. doi: 10.1172/JCI159825. J Clin Invest. 2022. PMID: 35289314 Free PMC article. No abstract available.
TGFβ shuts the door on T cells.
Bald T, Smyth MJ. Bald T, et al. Br J Cancer. 2018 Jul;119(1):1-3. doi: 10.1038/s41416-018-0122-x. Epub 2018 Jun 14. Br J Cancer. 2018. PMID: 29899392 Free PMC article.
T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis.
Briukhovetska D, Suarez-Gosalvez J, Voigt C, Markota A, Giannou AD, Schübel M, Jobst J, Zhang T, Dörr J, Märkl F, Majed L, Müller PJ, May P, Gottschlich A, Tokarew N, Lücke J, Oner A, Schwerdtfeger M, Andreu-Sanz D, Grünmeier R, Seifert M, Michaelides S, Hristov M, König LM, Cadilha BL, Mikhaylov O, Anders HJ, Rothenfusser S, Flavell RA, Cerezo-Wallis D, Tejedo C, Soengas MS, Bald T, Huber S, Endres S, Kobold S. Briukhovetska D, et al. Among authors: bald t. Immunity. 2023 Jan 10;56(1):143-161.e11. doi: 10.1016/j.immuni.2022.12.010. Immunity. 2023. PMID: 36630913 Free PMC article.
Innate Cancer Immunoediting.
Bald T, Smyth MJ. Bald T, et al. J Invest Dermatol. 2020 Apr;140(4):745-747. doi: 10.1016/j.jid.2019.09.015. J Invest Dermatol. 2020. PMID: 32200878 Free article.
74 results